Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer

Molecularly targeted cancer therapy has improved outcomes for patients with cancer with targetable oncoproteins, such as mutant EGFR in lung cancer. Yet, the long-term survival of these patients remains limited, because treatment responses are typically incomplete. One potential explanation for the...

Descripción completa

Detalles Bibliográficos
Autores principales: Nanjo, Shigeki, Wu, Wei, Karachaliou, Niki, Blakely, Collin M., Suzuki, Junji, Chou, Yu-Ting, Ali, Siraj M., Kerr, D. Lucas, Olivas, Victor R., Shue, Jonathan, Rotow, Julia, Mayekar, Manasi K., Haderk, Franziska, Chatterjee, Nilanjana, Urisman, Anatoly, Yeo, Jia Chi, Skanderup, Anders J., Tan, Aaron C., Tam, Wai Leong, Arrieta, Oscar, Hosomichi, Kazuyoshi, Nishiyama, Akihiro, Yano, Seiji, Kirichok, Yuriy, Tan, Daniel S.W., Rosell, Rafael, Okimoto, Ross A, Bivona, Trever G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246391/
https://www.ncbi.nlm.nih.gov/pubmed/35579943
http://dx.doi.org/10.1172/JCI145099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246391/
https://www.ncbi.nlm.nih.gov/pubmed/35579943
http://dx.doi.org/10.1172/JCI145099

Ejemplares similares